CSPC Group (01093) received a development milestone payment of US$15 million under an exclusive licensing agreement with CORBUS PHARMACEUTICALS for CRB -701 (SYS 6002)

Zhitongcaijing · 1d ago

Zhitong Financial App News, Shiyao Group (01093) issued an announcement regarding the conclusion of an exclusive licensing agreement for CRB -701 (SYS 6002) with Corbus Pharmaceuticals Inc. (Corbus Pharmaceuticals), a subsidiary of the Company. Giant Rock Biotech received a $15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. As of the date of this announcement, Jushi Biotech has received a total of US$32.5 million in down payments and development milestone payments from Corbus Pharmaceuticals under the agreement. The achievement of this milestone indicates that the relevant R&D work under the agreement is progressing steadily according to the plan.